Cost-Effectiveness of Therapeutic Use of Safety-Engineered Syringes in Healthcare Facilities in India.
Journal
Applied health economics and health policy
ISSN: 1179-1896
Titre abrégé: Appl Health Econ Health Policy
Pays: New Zealand
ID NLM: 101150314
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
20
11
2019
medline:
21
7
2021
entrez:
20
11
2019
Statut:
ppublish
Résumé
Globally, 16 billion injections are administered each year of which 95% are for curative care. India contributes 25-30% of the global injection load. Over 63% of these injections are reportedly unsafe or deemed unnecessary. To assess the incremental cost per quality-adjusted life-year (QALY) gained with the introduction of safety-engineered syringes (SES) as compared to disposable syringes for therapeutic care in India. A decision tree was used to compute the volume of needle-stick injuries (NSIs) and reuse episodes among healthcare professionals and the patient population. Subsequently, three separate Markov models were used to compute lifetime costs and QALYs for individuals infected with hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Three SES were evaluated-reuse prevention syringe (RUP), sharp injury prevention (SIP) syringe, and syringes with features of both RUP and SIP. A lifetime study horizon starting from a base year of 2017 was considered appropriate to cover all costs and consequences comprehensively. A systematic review was undertaken to assess the SES effects in terms of reduction in NSIs and reuse episodes. These were then modelled in terms of reduction in transmission of blood-borne infections, life-years and QALYs gained. Future costs and consequences were discounted at the rate of 3%. Incremental cost per QALY gained was computed to assess the cost-effectiveness. A probabilistic sensitivity analysis was undertaken to account for parameter uncertainties. The introduction of RUP, SIP and RUP + SIP syringes in India is estimated to incur an incremental cost of Indian National Rupee (INR) 61,028 (US$939), INR 7,768,215 (US$119,511) and INR 196,135 (US$3017) per QALY gained, respectively. A total of 96,296 HBV, 44,082 HCV and 5632 HIV deaths are estimated to be averted due to RUP in 20 years. RUP has an 84% probability to be cost-effective at a threshold of per capita gross domestic product (GDP). The RUP syringe can become cost saving at a unit price of INR 1.9. Similarly, SIP and RUP + SIP syringes can be cost-effective at a unit price of less than INR 1.2 and INR 5.9, respectively. RUP syringes are estimated to be cost-effective in the Indian context. SIP and RUP + SIP syringes are not cost-effective at the current unit prices. Efforts should be made to bring down the price of SES to improve its cost-effectiveness.
Sections du résumé
BACKGROUND
Globally, 16 billion injections are administered each year of which 95% are for curative care. India contributes 25-30% of the global injection load. Over 63% of these injections are reportedly unsafe or deemed unnecessary.
OBJECTIVES
To assess the incremental cost per quality-adjusted life-year (QALY) gained with the introduction of safety-engineered syringes (SES) as compared to disposable syringes for therapeutic care in India.
METHODS
A decision tree was used to compute the volume of needle-stick injuries (NSIs) and reuse episodes among healthcare professionals and the patient population. Subsequently, three separate Markov models were used to compute lifetime costs and QALYs for individuals infected with hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Three SES were evaluated-reuse prevention syringe (RUP), sharp injury prevention (SIP) syringe, and syringes with features of both RUP and SIP. A lifetime study horizon starting from a base year of 2017 was considered appropriate to cover all costs and consequences comprehensively. A systematic review was undertaken to assess the SES effects in terms of reduction in NSIs and reuse episodes. These were then modelled in terms of reduction in transmission of blood-borne infections, life-years and QALYs gained. Future costs and consequences were discounted at the rate of 3%. Incremental cost per QALY gained was computed to assess the cost-effectiveness. A probabilistic sensitivity analysis was undertaken to account for parameter uncertainties.
RESULTS
The introduction of RUP, SIP and RUP + SIP syringes in India is estimated to incur an incremental cost of Indian National Rupee (INR) 61,028 (US$939), INR 7,768,215 (US$119,511) and INR 196,135 (US$3017) per QALY gained, respectively. A total of 96,296 HBV, 44,082 HCV and 5632 HIV deaths are estimated to be averted due to RUP in 20 years. RUP has an 84% probability to be cost-effective at a threshold of per capita gross domestic product (GDP). The RUP syringe can become cost saving at a unit price of INR 1.9. Similarly, SIP and RUP + SIP syringes can be cost-effective at a unit price of less than INR 1.2 and INR 5.9, respectively.
CONCLUSION
RUP syringes are estimated to be cost-effective in the Indian context. SIP and RUP + SIP syringes are not cost-effective at the current unit prices. Efforts should be made to bring down the price of SES to improve its cost-effectiveness.
Identifiants
pubmed: 31741306
doi: 10.1007/s40258-019-00536-w
pii: 10.1007/s40258-019-00536-w
pmc: PMC7250963
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
393-411Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Références
Atul K, Priya R, Thakur R, Gupta V, Kotwal J, Seth T. Injection practices in a metropolis of North India: perceptions, determinants and issues of safety. Indian J Med Sci. 2004;58(8):334–44.
Handbook on safe injection practices. In: Control NCFD, editor. New Delhi: GOI; 2014.
Arora N. Injection practices in India. WHO South East Asia J Public Health. 2012;1(2):189–200.
pubmed: 28612794
Network, Safe Injection Global. Advocacy booklet. Switzerland: World Health Organization. 2011. p. 1–25
Gupta E, Bajpai M, Sharma P, Shah A, Sarin S. Unsafe injection practices: a potential weapon for the outbreak of blood borne viruses in the community. Ann Med Health Sci Res. 2013;3(2):177.
pubmed: 23919185
pmcid: 3728858
World Health Organization. WHO guideline on the use of safetyengineered syringes for intramuscular, intradermal and subcutaneous injections in health care settings. World Health Organization; 2016.
Solberg KE. Trade in medical waste causes deaths in India. Lancet. 2009;373(9669):1067.
pubmed: 19338068
Garapati SPS. Assessment of knowledge and practices on injection safety among service providers in east Godavari district of Andhra Pradesh. Indian J Comm Health. 2014;26(3):259–63.
Gaidhane A, Quazi Syed Z. Injection practices in India IPEN Study Group. WHO South East Asia J Public Health. 2012;1:189–200.
Pandit N, Choudhary S. Unsafe injection practices in Gujarat, India. Singap Med J. 2008;49(11):936.
Gita N, Rao N. Needle stick injuries in a tertiary care hospital in India: observations from a clinical audit. Int J Res Med Sci. 2017;5:2938–42.
Sikora C, Chandran AU, Joffe AM, Johnson D, Johnson M. Population risk of syringe reuse: estimating the probability of transmitting bloodborne disease. Infect Control Hosp Epidemiol. 2010;31(7):748–54.
pubmed: 20509761
Dziekan G, Chisholm D, Johns B, Rovira J, Hutin Y. The cost-effectiveness of policies for the safe and appropriate use of injection in healthcare settings. Bull World Health Organ. 2003;81:277–85.
pubmed: 12764494
pmcid: 2572434
Harb AC, Tarabay R, Diab B, Ballout RA, Khamassi S, Akl EA. Safety engineered injection devices for intramuscular, subcutaneous and intradermal injections in healthcare delivery settings: a systematic review and meta-analysis. BMC Nurs. 2015;14(1):71.
pubmed: 26722224
pmcid: 4697323
Batham A, Narula D, Toteja T, Sreenivas V, Puliyel JM. Systematic review and meta-analysis of prevalence of hepatitis B in India. Indian Pediatr. 2007;44(9):663.
pubmed: 17921555
Lahariya C, Subramanya B, Sosler S. An assessment of hepatitis B vaccine introduction in India: lessons for roll out and scale up of new vaccines in immunization programs. Indian J Public Health. 2013;57(1):8.
pubmed: 23649136
Nandi J, Bhawalkar V, Mody H, Elavia A, Desai PK, Banerjee K. Detection of HIV-1, HBV and HCV antibodies in blood donors from Surat, Western India. Vox Sang. 1994;67(4):406–7.
pubmed: 7535499
Sood A, Suryaprasad A, Trickey A, Kanchi S, Midha V, Foster M, et al. The burden of hepatitis C virus infection in Punjab, India: a population-based serosurvey. PLoS One. 2018;13(7):e0200461.
pubmed: 30048454
pmcid: 6061991
National AIDS Control Organization & ICMR-National Institute of Medical Statistics (2018). HIV Estimations 2017: Technical Report. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India. Available at: http://naco.gov.in/sites/default/file/HIV%20Estimations%202017%20Report_1.pdf .
GoI. National Health Policy-2017. Ministry of Health and Family Welfare. Government of India. 2017. Available at: https://mohfw.gov.in/documents/policy .
MOHFW. National Health Accounts: Estimates for India 2013–14. National Health Accounts Technical Secretariat (NHATS). National Health Systems Resource Centre (NHSRC). Ministry of Health and Family Welfare (MoHFW). Government of India. New Delhi; 2016.
Prinja S, Bahuguna P, Duseja A, Kaur M, Chawla YK. Cost of intensive care treatment for liver disorders at tertiary care level in India. PharmacoEconomics Open. 2018;2(2):179–90.
pubmed: 29623618
Prinja S, Kanavos P, Kumar R. Health care inequities in north India: role of public sector in universalizing health care. Indian J Med Res. 2012;136:421–31.
pubmed: 23041735
pmcid: 3510888
Prinja S, Kumar M, Pinto A, Jan S, Kumar R. Equity in hospital services utilization in India. Econ Polit Wkly. 2013;XLVIII(2):52–8.
Reid S. Estimating the burden of disease from unsafe injections in India: a cost–benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalence. Indian J Community Med. 2012;37(2):89–94.
pubmed: 22654281
pmcid: 3361807
Prinja S, Downey LE, Gauba VK, Swaminathan S. Health technology assessment for policy making in India: current scenario and way forward. New York: Springer; 2018.
Fukuda H, Moriwaki K. Cost-effectiveness analysis of safety-engineered devices. Infect Control Hosp Epidemiol. 2016;37(09):1012–21.
pubmed: 27226284
Prinja S, Bahuguna P, Rudra S, Gupta I, Kaur M, Mehendale SM, et al. Cost effectiveness of targeted HIV prevention interventions for female sex workers in India. Sex Transm Infect. 2011;87(4):354–61.
pubmed: 21447514
Saoji A, Kantibhushan C, Aniruddha D, Mudey A. Injection safety awareness and knowledge in a rural population. Glob J Health Sci. 2011;3(1):189–92.
The Economic Times: Forex Rates. 2017. http://economictimes.indiatimes.com/markets/forex . Accessed 2 Aug 2018.
GoI. Key Indicators of Social Consumption in India Health. NSS 71st Round. Ministry of Statistics and Program Implementation. Government of India. 2014.
Meshram RB, Gedam D. Prevalence of hepatitis B virus infection in general population of Nagpur Region. J Contemp Med Dent. 2015;3(2):48–50.
Prinja S, Balasubramanian D, Jeet G, Verma R, Kumar D, Bahuguna P, et al. Cost of delivering secondary-level health care services through public sector district hospitals in India. Indian J Med Res. 2017;146(3):354.
pubmed: 29355142
pmcid: 5793470
Sharma A, Prinja S, Sharma A, Gupta A, Arora SK. Cost of antiretroviral treatment for HIV patients in two centres of North India. Int J STD AIDS. 2019;30(8):769–78. https://doi.org/10.1177/0956462419839852 .
doi: 10.1177/0956462419839852
pubmed: 31081489
Younger B, Hunt EH, Robinson C, McLemore C. Impact of a shielded safety syringe on needlestick injuries among healthcare workers. Infect Control Hosp Epidemiol. 1992;13(6):349–53.
pubmed: 1619272
Prinja S, Gupta A, Verma R, Bahuguna P, Kumar D, Kaur M, et al. Cost of delivering health care services in public sector primary and community health centres in North India. PLoS One. 2016;11(8):e0160986. https://doi.org/10.1371/journal.pone .
doi: 10.1371/journal.pone
pubmed: 27536781
pmcid: 4990301
Chatterjee S, Levin C, Laxminarayan R. Unit cost of medical services at different hospitals in India. PLoS One. 2013;8(7):e69728.
pubmed: 23936088
pmcid: 3720595
Government of Punjab. Mukh Mantri Punjab Hepatitis-C Relief Fund (MMPHCRF)-One Year Journey. Punjab: Department of Health and Family Welfare, Punjab; 2017. 8 p. Available at: http://pbhealth.gov.in/Addendum_SOF_VEL%202018.pdf .
Sharma A, Prinja S, Sharma A, Gupta A, Arora SK. Cost of antiretroviral treatment for HIV patients in two centres of North India. Int J STD AIDS. 2019;30(8):769–78.
pubmed: 31081489
Personal Communication. Punjab State Health Department. Parivar Kalyan Bhawan Office, Chandigarh; 2017.
Higgins JP, Altman DG. Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions: Cochrane book series, pp. 187–241. 2008.
Hazarika I. Health workforce in India: assessment of availability, production and distribution. WHO South East Asia J Public Health. 2013;2(2):106.
pubmed: 28612768
Rehan HS, Chopra D, Sah RK, Chawla T, Agarwal A, Sharma GK. Injection practices of healthcare professionals in a Tertiary Care Hospital. J Infect Public Health. 2012;5(2):177–81.
pubmed: 22541265
Kermode M, Muani V. Injection practices in the formal & informal healthcare sectors in rural north India. Indian J Med Res. 2006;124(5):513–20.
pubmed: 17213519
Garapati S, Peethala S. Assessment of knowledge and practices on injection safety among service providers in east Godavari district of Andhra Pradesh. Indian J Community Health. 2014;26(3):259–63.
Sahu D, Gandhi N. Assessment of safe injection practices in a tertiary care hospital: a cross-sectional study from Chhattisgarh. Int J Community Med. 2015;6(4):500–3.
Rao KD, Bhatnagar A, Berman P. So many, yet few: human resources for health in India. Hum Resour Health. 2012;10:19.
pubmed: 22888906
pmcid: 3541981
Sood S, Malvankar S. Seroprevalence of Hepatitis B surface antigen, antibodies to the Hepatitis C virus, and human immunodeficiency virus in a hospital-based population in Jaipur, Rajasthan. Indian J Community Med. 2010;35(1):165.
pubmed: 20606944
pmcid: 2888349
Laghawe A, Faujdar S. Declining trends in HIV prevalence: a tertiary care hospital based 05 years retrospective analysis. Int J Curr Microbiol Appl Sci. 2015;4(6):927–36.
Goel V, Kumar D, Patwardhan V, Balooni V, Singhal S, Singh S. Trends of seroprevalence, epidemiology and clinical presentation of HIV in North India: a tertiary care hospital based study. World J AIDS. 2016;06(02):54–8.
WHO. Guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. Geneva: World Health Organization; 2019.
Prinja S, Gupta A, Bahuguna P, Nimesh R. Cost analysis of implementing mHealth intervention for maternal, newborn & child health care through community health workers: assessment of ReMIND program in Uttar Pradesh, India. BMC Pregnancy Childbirth. 2018;18(1):390.
pubmed: 30285669
pmcid: 6171293
Gouws E, White PJ, Stover J, Brown T. Short term estimates of adult HIV incidence by mode of transmission: Kenya and Thailand as examples. Sex Transm Infect. 2006;82(suppl 3):iii51–5.
pubmed: 16735294
pmcid: 2576735
Korenromp EL, Nagelkerke NJ, Habbema JDF. Estimating the magnitude of STD cofactor effects on HIV transmission: how well can it be done? Sex Transm Dis. 2001;28(11):613–21.
pubmed: 11677381
van der Molen HF, Zwinderman KAH, Sluiter JK, Frings-Dresen MHW. Better effect of the use of a needle safety device in combination with an interactive workshop to prevent needle stick injuries. Saf Sci. 2011;49(8–9):1180–6.
Whitby M, McLaws M-L, Slater K. Needlestick injuries in a major teaching hospital: the worthwhile effect of hospital-wide replacement of conventional hollow-bore needles. Am J Infect Control. 2008;36(3):180–6.
pubmed: 18371513
Sikora C, Chandran AU, Joffe AM, Johnson D, Johnson M. Population risk of syringe reuse: estimating the probability of transmitting bloodborne disease. Infect Control Hosp Epidemiol. 2010;31(07):748–54.
pubmed: 20509761
Weinstein M, Grahan J, Siegel J, et al. Cost-effectiveness analysis of AIDS prevention programs: concepts, complications and illustrations. In: Turner C, Miller H, Moses L, editors. AIDS: sexual behaviour and intravenous drug use. Washington, DC: National Academy Press; 1989.
Alazawi W, Cunningham M, Dearden J, Foster G. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32:344–55.
pubmed: 20497143
Alberti A, Chemello L, Benvegnù L. Natural history of hepatitis C. J Hepatol. 1999;31(1):17–24.
pubmed: 10622555
Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57:230–6.
pubmed: 23616492
Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis. 2006;10(4):697–715.
pubmed: 17164113
Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Rof L, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol. 2009;104:1147–58.
pubmed: 19352340
Chen S, Morgan T. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3(2):47–52.
pubmed: 16614742
pmcid: 1415841
Degos F, Christidis C, Ganne-Carrie N, Farmachidi J, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131–6.
pubmed: 10861275
pmcid: 1727946
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52.
pubmed: 18096267
Gramenzi A, Andreone P, Fiorino S, Cammà C, Giunta M, Magalotti D, et al. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut. 2001;48:843–8.
pubmed: 11358906
pmcid: 1728334
Kobayashi M, Ikeda K, Hosaka T, Sezaki H, Someya T, Akuta N, et al. Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol. 2006;78:459–65.
pubmed: 16482557
Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, et al. The impact of chronic hepatitis b on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health. 2008;11(3):527–38.
pubmed: 18179664
Simpson KN, Luo MP, Chumney E, Sun E, Brun S, Ashraf T. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004;5(5):294–304.
pubmed: 15562370
Wright M, Grieve R, Roberts J, Main J, Thomas H. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess. 2006;10(21):1–250.
pubmed: 16750059
Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny M-P, et al. Cost–effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925.
pubmed: 27994285
pmcid: 5153921
Prinja S, Downey L, Gauba V, Swaminathan S. Health technology assessment for policy making in india: current scenario and way forward. PharmacoEconomics Open. 2018;2:1–3.
pubmed: 29464668
Prinja S, Chauhan AS, Angell B, Gupta I, Jan S. A systematic review of the state of economic evaluation for health care in India. Appl Health Econ Health Policy. 2015;13(6):595–613.
pubmed: 26449485
Chugh Y, Dhiman RK, Premkumar M, Prinja S, Singh Grover G, Bahuguna P. Real-world cost-effectiveness of pan-genotypic Sofosbuvir–Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India. PLoS One. 2019;14(8):e0221769.
pubmed: 31465503
pmcid: 6715223
Prinja S, Bahuguna P, Faujdar DS, Jyani G, Srinivasan R, Ghoshal S, et al. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: implications for India’s universal immunization program. Cancer. 2017;123(17):3253–60.
pubmed: 28472550
John MJ, Jyani G, Jindal A, Mashon RS, Mathew A, Kakkar S, et al. Cost effectiveness of hematopoietic stem cell transplantation compared with transfusion chelation for treatment of thalassemia major. Biol Blood Marrow Transplant. 2018;24(10):2119–26.
pubmed: 29673692
Prinja S, Nimesh R, Gupta A, Bahuguna P, Thakur JS, Gupta M, et al. Impact assessment and cost-effectiveness of m-health application used by community health workers for maternal, newborn and child health care services in rural Uttar Pradesh, India: a study protocol. Glob Health Action. 2016;9(1):31473.
pubmed: 27189200
Research DoH. Health Technology Assessment in India: A Manual. New Delhi. In: Department of Health Research MoHaFW, Government of India., editor. 2018.
Andronis L, Barton P, Bryan S. Sensitivity analysis in economic evaluation: an audit of NICE current practice and review of its use and value in decision-making. Health Technol Assess. 2009. https://doi.org/10.3310/hta13290 .
doi: 10.3310/hta13290
pubmed: 19846023
Briggs A. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479–500.
pubmed: 10977389
Briggs A, Claxton K, Schulpher M. Decision modelling for health economic evaluation, vol. Chapter 4. Oxford University Press; 2006. p. 86–92.
Briggs A, Gray A. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess. 1999;3(2):iii-72.
Hoffmann C, Buchholz L, Schnitzler P. Reduction of needlestick injuries in healthcare personnel at a university hospital using safety devices. J Occup Med Toxicol. 2013;8(1):20.
pubmed: 23895578
pmcid: 3728001
Whitby M, Stead P, Najman JM. Needlestick injury: impact of a recapping device and an associated education program. Infect Control Hosp Epidemiol. 1991;12(4):220–5.
pubmed: 2061580
Wolf BL, Marks A, Fahrenholz JM. Accidental needle sticks, the occupational safety and health administration, and the fallacy of public policy. Ann Allergy Asthma Immunol. 2006;97(1):52–4.
pubmed: 16892781
Steinglass R, Boyd D, Grabowsky M, Laghari A, Khan M, Qavi A, et al. Safety, effectiveness and ease of use of a non-reusable syringe in a developing country immunization programme. Bull World Health Organ. 1995;73(1):57.
pubmed: 7704926
pmcid: 2486573
Duesman K, Ross J. Survey of accidental needlesticks in 26 facilities using Vanishpoint automated retraction syringe. J Healthc Saf Compliance Infect Control. 1998;2(3):111–4.
Chambers A, Mustard C, Etches J. Trends in needlestick injury incidence following regulatory change in Ontario, Canada (2004–2012): an observational study. BMC Health Serv Res. 2015;15(1):127.
pubmed: 25880621
pmcid: 4393628
Japan Ministry of Health, Labour and Welfare. Points of attention for hospital-acquired infection control in healthcare institutions. Guidance of Medical Service Division, Health Policy Bureau Notification No. 0617-1 (June 17, 2011). http://www.mhlw.go.jp/topics/2012/01/dl/tp0118-1-76.pdf ). Accessed 15 Nov 2018.
Department of Health, The Government of South Africa. https://www.westerncape.gov.za/general-publication/immunisation-safe . Accessed 3 Feb 2019.
Cooke C, Stephens J. Clinical, economic, and humanistic burden of needlestick injuries in healthcare workers. Med Devices Evid Res. 2017;10:225–35.
Hanmore E, Maclaine G, Garin F, Alonso A, Leroy N, Ruff L. Economic benefits of safety-engineered sharp devices in Belgium—a budget impact model. BMC Health Serv Res. 2013;13(1):489.
pubmed: 24274747
pmcid: 4222860
Glenngård AH, Persson U. Costs associated with sharps injuries in the Swedish health care setting and potential cost savings from needle-stick prevention devices with needle and syringe. Scand J Infect Dis. 2009;41(4):296–302.
pubmed: 19229763
Ashat M, Bhatia V, Puri S, Thakare M, Koushal V. Needle stick injury and HIV risk among health care workers in North India. Indian J Med Sci. 2011;65(9):371–8.
pubmed: 23508479
Arora A, Gupta A, Sharma S. Knowledge, attitude and practices on needle-stick and sharps injuries in tertiary care cardiac hospital: a survey. Indian J Med Sci. 2010;64(9):396.
pubmed: 23006418
Goel V, Kumar D, Lingaiah R, Singh S. Occurrence of needlestick and injuries among health-care workers of a tertiary care teaching hospital in north India. J Lab Phys. 2017;9(1):20–5.
Health in India- NSS 71st Round National Sample Survey Office;New Delhi: Ministry of Statistics and Programme Implementation; 2014. http://mospi.nic.in/sites/default/files/publication_reports/nss_rep574.pdf . Accessed 10 Nov 2018.
Kanodia V, Yadav M, Bittu R, Maheshwari R, Singh S. Seroprevalence of Hepatitis B surface antigen in hospital based population of Jaipur, Rajasthan. MedPulse Int Med J. 2015;2:123–5.
Bharadwaj BVG, Vazhavandal G, Uma A, Rajalakshmi PC. Seroprevalence of hepatitis C virus infection among patients attending a rural teaching hospital in South India: a three year study. Int J Curr Microbiol Appl Sci. 2014;3(2):123–7.
Association OH. Blood-borne diseases surveillance protocol for Ontario hospitals. 2015.
Prevention CfDCa. In: Division of Viral Hepatitis NCfHA, Viral Hepatitis, STD, and TB Prevention, editor.
Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS. Updated US Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. Morb Mortal Wkly Rep Recomm Rep. 2005;54(9):1-CE-4.
HIV Transmission risk: a summary of the evidence infectious disease prevention and control. 2012.
Boily M-C, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009;9(2):118–29.
pubmed: 19179227
pmcid: 4467783
Vitinghoff E, Douglas J, Judon F, McKiman D, MacQueen K, Buchinder SP. Per-contact risk of human immunodificiency virus tramnsmision between male sexual partners. Am J Epidemiol. 1999;150(3):306–11.
Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, de Bruyn G, et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1–serodiscordant couples. J Infect Dis. 2012;205(3):358–65.
pubmed: 22241800
pmcid: 3256946
Inoue T, Tanaka Y. Hepatitis B virus and its sexually transmitted infection-an update. Microbial Cell. 2016;3(9):420.
pubmed: 28357379
pmcid: 5354569
Fazili Anjum B, Iqbal Qazi M, Mushtaq B, Shah Rohul J, Ganai Abdul M. Study on hepatitis B vaccination coverage among workforce of a tertiary care hospital in North India. Health Sci. 2016;5(5):115–20.
Debbarma M, Gogoi S, Jais M, Kaur R. Awareness and status of hepatitis B vaccination among health care workers in a tertiary care centre of North India. Br J Med Health Res. 2016;3:83–91.
Sujatha RNP, Arunagiri D, Narendran D. Seroprevalence and risk factors of hepatitis-B infection in patients attending a tertiary care center in Kanpur [UP]India. Int J Curr Med Appl Sci. 2014;4(3):98–103.
Geeta MGRA. Prevention of mother to child transmission of hepatitis B infection. Indian Pediatr. 2019;50(2):189–92.